Application Spotlight: Custom GMP Workstation for T Cell Therapy

A custom modular GMP suite of workstations will be used for Cell Therapy. The customer, based in the South of England, is working on a novel new approach to T Cell therapy whereby they are building up a stock of T Cells derived from healthy donors which can be administered to cancer patients.

The system consists of three sections. Section 1 is a H135 HEPA workstation, Section 2 is aH155 GMP workstation, and Section 3 is a refrigerated H135 HEPA workstation. Each section will be attached through a shared airlock.This is represented in the illustration below:


Read more: Application Spotlight: Custom GMP Workstation for T Cell Therapy

The Brain and Hypoxia

July 22,2021
Don Whitley Scientific


Being arguably the most important organ in the human body, research into the brain is ever-growing. The World Federation of Neurology hold an annual day dedicated to improving the quality of neurology and brain health [1]. Research into brain injury is incredibly important, with one of the causes of such injury being hypoxia [2]. This is because brain cells have a high sensitivity to oxygen, so when cerebral hypoxia occurs, the cells die within minutes causing severe brain damage [2]. Less severe damage is also observed in tissues surrounding the hypoxic region [2].

Read more: The Brain and Hypoxia

COVID-19 Researcher Using H35 Hypoxystation


January 4, 2021

Dr James Nathan is Reader in Respiratory Medicine at the University of Cambridge, and Group Leader at the Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID).

Dr Nathan (pictured) is a trained respiratory physician who has carried out extensive research at Harvard, and Cambridge Universities. He set up his own lab in 2013 focusing on how cells sense and adapt to oxygen and nutrients in addition to how this impacts certain diseases. Since March 2020, his group has been conducting research into how low oxygen (hypoxia) affects COVID-19 infected patients.

Read more: COVID-19 Researcher Using H35 Hypoxystation

A new first in the fight against cancer from Don Whitley Scientific

February 2, 2021

Press Release

2 2 2021DW1

The PRECISE Group at the University of Manchester (pictured above), The Christie NHS Foundation Trust and Don Whitley Scientific today announced the world’s first Proton Radiobiology Modified Atmosphere Workstation with integrated robotic arm, which will be used for research into cancer treatments. The Proton Beam Therapy Centre at The Christie, Manchester, is the first NHS high energy proton beam therapy centre in the UK. Within the facility there is a dedicated research room, which was funded by The Christie Charity, where this new Whitley Workstation will be operated. The workstation with its integrated robotic arm was funded by CRUK Manchester Major Centre funding.

Read more: A new first in the fight against cancer from Don Whitley Scientific

Kidney Cancer Study at the University of Utah

Date: August 17, 2020


Omar Hussain, Product Specialist at Don Whitley Scientific, provides a synopsis of a paper by Dr Sophie Cowman et al, University of Utah. Their research looked at clear cell renal cell carcinoma (ccRCC), which is frequently associated with inactivation of the von Hippel Lindau tumour suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumour promoting role for HIF-2α, and a tumour suppressor role for HIF-1α. The paper is entitled:

“Macrophage HIF-1α is an independent prognostic indicator in kidney cancer”

This is something that has not been comprehensively studied before and was carried out by assessing the involvement of hypoxia associated factors/hypoxia inducible factors and their relationship to tumour grade/stage/outcome using tissue from 380 patients.

Read more: Kidney Cancer Study at the University of Utah